{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T23:43:12Z","timestamp":1785714192349,"version":"3.56.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.clml.2016.04.017","type":"journal-article","created":{"date-parts":[[2016,5,5]],"date-time":"2016-05-05T16:24:51Z","timestamp":1462465491000},"page":"466-471.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?"],"prefix":"10.1016","volume":"16","author":[{"given":"Zachariah","family":"DeFilipp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia A.","family":"Langston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengjia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha L.","family":"Arellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuad","family":"El Rassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Flowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vamsi K.","family":"Kota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaid","family":"Al-Kadhimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7280-9755","authenticated-orcid":false,"given":"Rachel","family":"Veldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand P.","family":"Jillella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund K.","family":"Waller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna J.","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2016.04.017_bib1","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1200\/JCO.2011.34.7146","article-title":"Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008","volume":"29","author":"Bjorkholm","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.04.017_bib2","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1182\/blood-2011-08-358135","article-title":"Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.04.017_bib3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.clml.2013.08.008","article-title":"Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase","volume":"14","author":"Ohanian","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2016.04.017_bib4","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3324\/haematol.2014.118588","article-title":"Final report of a phase II study of imatinib mesylate with hyper-CVAD for the frontline treatment of adult patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia","volume":"100","author":"Daver","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2016.04.017_bib5","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1182\/blood-2009-12-261586","article-title":"First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia","volume":"116","author":"Ravandi","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.04.017_bib6","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11899-015-0249-2","article-title":"Management of advanced-phase chronic myeloid leukemia","volume":"10","author":"DeFilipp","year":"2015","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clml.2016.04.017_bib7","first-page":"513","volume":"91","author":"Gratwohl","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2016.04.017_bib8","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/leu.2013.253","article-title":"Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease","volume":"28","author":"Bachanova","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2016.04.017_bib9","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.bbmt.2009.08.019","article-title":"Current status and perspectives of tyrosine kinase inhibitor treatment in the posttransplant period in patients with chronic myelogenous leukemia (CML)","volume":"16","author":"Klyuchnikov","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2016.04.017_bib10","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2006-04-019836","article-title":"Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia","volume":"109","author":"Carpenter","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.04.017_bib11","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1182\/blood-2007-04-082990","article-title":"Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia","volume":"110","author":"Olavarria","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.04.017_bib12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1756-8722-5-29","article-title":"Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia","volume":"5","author":"Chen","year":"2012","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clml.2016.04.017_bib13","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.04.017_bib14","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"key":"10.1016\/j.clml.2016.04.017_bib15","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2016.04.017_bib16","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/bmt.2011.194","article-title":"Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis","volume":"47","author":"Khoury","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2016.04.017_bib17","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1182\/blood-2004-05-1746","article-title":"Early molecular response to\u00a0posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)","volume":"106","author":"Wassmann","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.04.017_bib18","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.bbmt.2004.09.004","article-title":"Re: Imatinib mesylate administration in the first 100 days after stem cell transplantation","volume":"10","author":"Anderlini","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2016.04.017_bib19","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000228587","article-title":"Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia","volume":"122","author":"Klyuchnikov","year":"2009","journal-title":"Acta Haematol"},{"key":"10.1016\/j.clml.2016.04.017_bib20","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.bbmt.2011.12.587","article-title":"Prophylactic and preemptive therapy with dasatinib after hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"18","author":"Caocci","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2016.04.017_bib21","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/cncr.23666","article-title":"Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors","volume":"113","author":"Jones","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2016.04.017_bib22","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/leu.2012.352","article-title":"Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia","volume":"27","author":"Pfeifer","year":"2013","journal-title":"Leukemia"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226501630060X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226501630060X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:27:23Z","timestamp":1761870443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226501630060X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S215226501630060X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2016.04.017","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2016.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}